SCHEMBL3010706

SCHEMBL3010706

COc1ccc(Br)cc1S(=O)(=O)C1CCN(c2nc(-c3cc(Cl)cc(Cl)c3)cs2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 11/20 0.46
RAB9A P51151 9/20 0.46
NPC1 O15118 6/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPT P10636 5/20 0.44
GAA P10253 3/20 0.42
MAPK1 P28482 2/20 0.42
ALDH1A1 P00352 1/20 0.42
PTPN1 P18031 1/20 0.40
PTPN6 P29350 1/20 0.40
CDC25A P30304 1/20 0.40
KDM4E B2RXH2 1/20 0.40
NTSR1 P30989 1/20 0.40
RECQL P46063 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
LMNA P02545 1/20 0.39
ALOX15 P16050 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016553 0.95 SMN1; SMN2 (0.42) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL3003922 0.94 RAB9A (0.49) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL3008094 0.92 SMN1; SMN2 (0.49) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL3013516 0.91 GAA (0.54) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL3019666 0.91 RAB9A (0.48) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL3020871 0.91 SMN1; SMN2 (0.46) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL3018828 0.90 AR (0.48) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL3015447 0.90 SMN1; SMN2 (0.45) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL3009453 0.90 RAB9A (0.51) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL3008913 0.90 SMN1; SMN2 (0.57) SMN1; SMN2RAB9ANPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.